Universitat de Lleida
    • English
    • català
    • español
  • español 
    • English
    • català
    • español
  • Mi DSpace
Repositori Obert UdL
Ver ítem 
  •   DSpace Principal
  • Recerca
  • Ciències Mèdiques Bàsiques
  • Articles publicats (Ciències Mèdiques Bàsiques)
  • Ver ítem
  •   DSpace Principal
  • Recerca
  • Ciències Mèdiques Bàsiques
  • Articles publicats (Ciències Mèdiques Bàsiques)
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

T-type Ca2+ Channels: T for Targetable

Thumbnail
Ver/Abrir
Postprint (1.388Mb)
Fecha de publicación
2018-01-17
Autor/a
Crespí Sallán, Marta
Visa, Anna
Shaikh, Soni
Nàger Grifo, Mireia
Herreros Danés, Judit
Cantí Nicolás, Carles
Impacto


Logo de Web of Science    citaciones en Web of Science

Logo de Scopus    citaciones en Scopus

Logo de Google Académico  Google Académico
Compartir
Exportar a Mendeley
Metadatos
Mostrar el registro completo del ítem
Resumen
In the last decade TTCC have been unveiled as key regulators of cancer cells biology and thus have been proposed as chemotherapeutic targets. Indeed in vitro and in vivo studies indicate that TTCC pharmacological blockers have a negative impact on the viability of cancer cells and reduce tumor size,
respectively. Consequently mibefradil, a TTCC blocker approved in 1997 as an antihypertensive agent but withdrawn in 1998 because of drug-drug interactions, was granted 10 years later the orphan drug status by the FDA to investigate its efficacy against brain, ovary and pancreatic cancer. However, the existence of different channel isoforms with distinct physiological roles, together with the lack of selective pharmacological agents, has hindered a conclusive chemotherapeutic evaluation. Here we review the available evidence on TTCC expression, value as prognostic markers and effectiveness of their pharmacological blockade on cancer cells in vitro and in preclinical models. We additionally summarize the status of clinical trials using mibefradil against glioblastoma multiforme. Finally, we discuss the future perspectives and the importance of further development of multidisciplinary research efforts on the consideration of TTCC as biomarkers or targetable molecules in cancer.
URI
http://hdl.handle.net/10459.1/62653
DOI
https://doi.org/10.1158/0008-5472.CAN-17-3061
Es parte de
Cancer Research, 2018, vol. 78, num. 3, p. 1-7
Colecciones
  • Articles publicats (IRBLleida) [594]
  • Articles publicats (Medicina Experimental) [203]
  • Articles publicats (Ciències Mèdiques Bàsiques) [415]

Contacto | Sugerencias | Aviso legal
© 2019 BiD. Universitat de Lleida
Metadades subjectes a
 

 

Listar

Todo DSpaceComunidades y coleccionesPor fecha de publicaciónAutoresTítulosMateriasEsta colecciónPor fecha de publicaciónAutoresTítulosMaterias

Estadísticas

Ver Estadísticas de uso

D'interès

Política institucional d'accés obertDiposita les teves publicacionsDiposita dades de recercaSuport a la recerca

Contacto | Sugerencias | Aviso legal
© 2019 BiD. Universitat de Lleida
Metadades subjectes a